All In Biotech

Drug Trial Radar · NCT01396213

A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Different Doses of Larazotide Acetate for the Treatment of Celiac Disease

Last checked: Nov 19, 2026Latest source record: Sep 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 342 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

342

Actual

Start

Nov 7, 2011

Primary completion

Aug 20, 2013

Study completion Aug 20, 2013

Sponsor

Lead sponsor
9 Meters Biopharma, Inc.Industry
Sponsor type
Industry
Collaborators
Teva Pharmaceuticals USA
First posted
Jul 18, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo-controlled Phase 2B study to evaluate the efficacy and safety of Larazotide Acetate in the treatment of patients with celiac disease who have persistent symptoms despite being on a gluten-free diet.

Conditions

  • Celiac Disease

Interventions

  • Larazotide AcetateDrug

    gelatin capsule

  • placeboDrug

    gelatin capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the efficacy of larazotide acetate versus placebo for the treatment of celiac disease in adults as an adjunct to a gluten-free dietTime frame: CeD GSRS was completed weekly Baseline through the end of 12-week double-blind treatment period.

Locations

62 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Mesa, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Oceanside, California

  • Site not named

    Orange, California

  • Site not named

    San Francisco, California

  • Site not named

    Santa Monica, California

  • Site not named

    Walnut Creek, California

  • Site not named

    Denver, Colorado

  • Site not named

    Boynton Beach, Florida

  • Site not named

    Edgewater, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Summerfield, Florida

  • Site not named

    Marietta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Rockford, Illinois

  • Site not named

    West Des Moines, Iowa

  • Site not named

    Wichita, Kansas

  • Site not named

    Lexington, Kentucky

  • Site not named

    Louisville, Kentucky

  • Site not named

    Baltimore, Maryland

  • Site not named

    Hagerstown, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Chesterfield, Michigan

  • Site not named

    Wyoming, Michigan

  • Site not named

    Duluth, Minnesota

  • Site not named

    Rochester, Minnesota

  • Site not named

    Jackson, Mississippi

  • Site not named

    St Louis, Missouri

  • Site not named

    Missoula, Montana

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Marlton, New Jersey

  • Site not named

    Lake Success, New York

  • Site not named

    New York, New York

  • Site not named

    New York, New York

  • Site not named

    Rochester, New York

  • Site not named

    Cary, North Carolina

  • Site not named

    Salisbury, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Cleveland, Ohio

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.